Skip to main content
. 2022 Jul 17;77(1):20–32. doi: 10.1002/hep.32599

FIGURE 2.

FIGURE 2

Serum IL‐31 levels in patients with NASH administered cilofexor. (A) CILO increased serum IL‐31 in a dose‐dependent manner. (B) Serum IL‐31 levels were significantly higher in patients with NASH receiving CILO 100 mg who had severe pruritus (Grades 2–3) compared to patients with none or mild pruritus (Grades 0–1). (C) Patients with NASH had greater increase of serum IL‐31 levels than healthy volunteers (HVs) after cilofexor administration. (D) The increase of serum IL‐31 had a temporal correlation with serum FGF‐19 changes in both HVs and patients with NASH. (E) Changes of serum IL‐31 and C4 from baseline to Week (W)24 in the cilofexor 100 mg group were significantly negatively correlated. CILO, cilofexor; FGF, fibroblast growth factor; IQR, interquartile range; ns, not significant; PBO, placebo; TEAE, treatment‐emergent adverse event.